Adlyfe is a privately held early stage biotechnology company that utilizes novel and proprietary peptide technology to develop solutions for early detection of protein misfolding diseases. Our Team consists of industry leaders with deep experience in the pharmaceutical/biotech industry. Since the company’s inception Adlyfe has developed a robust, diversified approach toward the development of molecular biomarkers, in particular for Alzheimer’s Disease, to present viable opportunities for the development of novel assays with commercial potential. The value of the approach has been validated by investments from prestigious investors like Burrill Venture Group, Canaan Partners and the Maryland Venture Fund, as well as by an early partnership with Wyeth (now Pfizer). The company’s mission is to continue to advance its technology, providing hope for those suffering from neurodegenerative disease.